

# INTERNAL PRODUCT MONOGRAPH: MINOCYCLINE HCI

**Brand Name:** MinoClear™

**Molecule:** Minocycline Hydrochloride

**Therapy Area:** Dermatology / Anti-Infective

**Status:** Legacy Product (Mature)

**Document Owner:** Global Product Management (Dermatology)

## 1. Product Overview

Minocycline is a broad-spectrum tetracycline antibiotic. It is highly lipophilic, allowing for excellent tissue penetration. AstraGen is currently the #2 global supplier of generic Minocycline capsules.

### Current Indications:

- Inflammatory lesions of non-nodular moderate to severe acne vulgaris.
- Adjunctive therapy for severe acne.
- Treatment of carrier state of *Neisseria meningitidis* (rare use).

## 2. Supply Chain & Manufacturing Status

- **Manufacturing Site:** Baddi Unit III (Dedicated Block).
- **API Inventory Status:** **CRITICAL SURPLUS.** \* Current API Stockpile: 4,500 kg (approx. 18 months of cover).
  - Reason for Surplus: Unexpected drop in US prescriptions due to new topical competitors and isotretinoin adoption.
  - **Risk:** API shelf-life expiration risk by Q4 2026 if volume does not increase.

## 3. Commercial Performance (Q2 2025)

- **Revenue Trend:** -4.5% YoY (Declining).
- **Market Share:** Holding steady at 18%, but the total addressable market (TAM) for oral acne antibiotics is shrinking.
- **Margin:** High (due to fully depreciated manufacturing assets), but volume is the constraint.

## 4. Clinical Observations & Off-Label Signals

Field force reports and Medical Science Liaison (MSL) notes indicate growing off-label interest from outside Dermatology:

- **Rheumatology:** Anecdotal use in Rheumatoid Arthritis (RA) due to anti-inflammatory effects.
- **Neurology:** Several inquiries regarding **neuroprotective properties**. Unlike other tetracyclines, Minocycline effectively crosses the **Blood-Brain Barrier (BBB)**.
- **Psychiatry:** Isolated reports of use in treatment-resistant depression with inflammatory biomarkers.

## 5. Strategic Recommendation

**URGENT:** The Product Committee recommends initiating a feasibility study to re-brand or re-formulate Minocycline for a non-dermatological indication to utilize the Baddi API surplus.

*CONFIDENTIAL: For Internal Use Only.*